Viking Therapeutics (VKTX) 26 Jul 232023 Q2 Earnings call transcript

Welcome to the Viking Therapeutics Second Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Following management’s prepared remarks, we will hold a Q&A session. [Operator Instructions] As a reminder, this conference call is being recorded today, July 26, 2023.

I would now like to turn the conference over to Viking’s Manager of Investor Relations, Stephanie Diaz. Stephanie. ahead, go Please

you participating thank today’s all and in for call. Hello

Viking’s today CEO; is me President Brian CFO. Joining Viking’s Lian, and Zante, and Greg

made and Private forward-looking about its statements I caution the including Safe today, begin, statements like of under milestones. Reform XX, during the development Act provisions comments XXXX, U.S. July contain we regarding call Litigation this activities, Viking’s will Before XXXX, expectations Harbor timelines conference Securities would that to of

risks and to to of that could adversely Forward-looking reported results subject statements not indication uncertainties cause actual as differ and are future performance. an and materially be results should considered

encourage of no the of to filings forward-looking speak or other review with statement revise company’s These Exchange and the and and I the any these today’s obligation only Commission you to matters. company concerning undertakes as all update statements Securities today. date, made

his will turn Lian the call over Brian to initial for I comments. now

listening by operations. good Thanks, the afternoon and update or and months results and financial review second with Stephanie, webcast. of dialled quarter for provide progress clinical first our to in Today, on and an our six programs we'll phone on XXXX, everyone recent the

clinical Viking, a The with programs two our XXXX support of exceptional pipeline. financing has announcing the positive first to half completing been data successful the of for from company and continued development

positive announced its biopsy treatment Xb VKXXXX's Phase achieved NASH. the quarter, therapeutic confirming VOYAGE VKXXXX, from study second steatohepatitis nonalcoholic for confirmed with best-in-class results or in endpoint, the of the patients we NASH. of During primary profile successfully Study The

oral encouraging a for This dose and potential X tolerability we also first from of also X we will initiation call. announced GIP today's these treatment of VKXXXX, demonstrated ascending signs receptor year, the results study and ascending new results formulation safety Along clinical agonists, novel the data the of clinical Phase with half and of XX first I days study single multiple treatment. to of study review this a VKXXXX, activity of later for of GLP-X the clinical dose our following dual and Phase compound. a positive clinical in the obesity. In announced evaluate

review year, public during of closing of programs the through common million provide the our of quarter the further and clinical operations second stock, second offering quarter a for results months each proceeds I'll of XXXX. first $XXX successful announced our and raising of of we details we the of that milestones. for to plan Finally, advancement our continued key gross development activities the approximately on financial use we after six

For that, call Chief to I'll Officer. over turn Financial Viking Zante, the

today. I'd file filing my six with XX-Q months In ended Brian. to beginning comments, with Commission, to participants results which go I'll for refer the Exchange XX, quarter quarter. our over like June we the now the conjunction Thanks, results for expect Vikings the recommend that XXXX, with and Securities second Form to and

increase XXXX, third-party studies, and to related decreased was and to three to our clinical partially expenses June compared Research The in expenses for compensation, consultants, drug benefits were stock-based manufacturing offset of $XX.X the XX, $XX.X period primarily ended related for development studies. months expenses the salaries by million for candidates, pre-clinical XXXX. same million due increased to

salaries compensation period was increase to June administrative three services, same $X.X XX, in and The XXXX. to stock-based related primarily XXXX, expenses ended months benefits. patent compared for and the $X.X million legal the and to increased due for and general Our were expenses million

$XX.X the to ended in share the XXXX. million net period months net the primarily period compared ended or previously, share For corresponding in due in XXXX, loss reported per million Viking XX, of $X.XX per and same The a expenses, XXXX. compared of months partially the a or for offset administrative June in three the loss $XX.X net three income increased general to increase to by loss XX, interest increase June in was noted XXXX $X.XX

period compensation, in manufacturing by candidates, clinical related over XX, for expenses the benefits the results salaries ended $XX.X primarily XXXX. XXXX. for go related $XX.X partially drug and decrease months due to June The development million was compared to XXXX regulatory the expenses stock-based and June our I'll offset six Research ended XX, expenses million to and studies, for to decreased the services. increased six now same were for months

to period compensation were Our and due general million related XXXX and XXXX. administrative increased patent salaries same million to for increase ended compared $X.X XX, and stock-based June primarily benefits. expenses The and to $XX.X in for expenses services, the months legal the six was

six XXXX, net June months a a $X.XX $XX.X of million share of loss compared or XX, million $XX.X per the Viking For $X.XX net of period or in the ended reported corresponding XXXX. to loss share per

the the due loss net June primarily in XXXX. offset general for income XX, partially period to the in same in previously, was XXXX to noted increase administrative increased interest expenses compared and months ended increase six by The

Turning to cash, of Viking $XXX.X XX, million short-term sheet, of $XXX.X held million XXXX. compared balance equivalents the December and investments as XXXX, at cash to June XX,

turn now my review concludes This call financial Brian. and back the to I'll over

receptor molecule with VKXXXX. available, thyroid as small of isoform tissue an my VKXXXX likeness Greg. the the selected comments is our update program, the I'll receptor. is beta lead an for on that hormone well to liver orally as Thanks, begin

to were primary the quarter, second VKXXXX with from this to significant NASH very week experiencing VKXXXX liver content fat with that patients During endpoint compared announced patients confirmed Phase results in VOYAGE company positive receiving Xb pleased achieved fibrosis. statistically with XX biopsy in baseline evaluating from study its topline report the the reductions as study placebo. and We

from relative VKXXXX. by to imaging magnetic among assessed XX% ranged median fraction resonance fat from The density change patients as in proton fat liver baseline XX% receiving

greater benefit efficacy in in reduction This fat likelihood a of to relative Importantly, VKXXXX experienced content. the up histologic XX% liver XX% level patients receiving of with NASH. associated of least at is

important development elevations with statistically unique a patients Additionally, In evaluating risk. its cardiovascular that programs treated the low all and number density VKXXXX Xb other been of which be lipoprotein reductions cardiovascular It contrast, triglycerides data have following VK-XXXX in cholesterol, studies highlight demonstrated Phase that to correlated have may atherogenic is demonstrated lipids lipoproteins, of to indicate offer treatment. in potential VOYAGE in benefit. NASH these protective a significant

tolerability among mild this arms. treatment Discontinuations among important encouraging and receiving due low events XX% VK-XXXX of placebo adverse to as demonstrated and treatment-related and or Also balanced in events were patients VK-XXXX reported were adverse safety study. moderate.

study. stool frequency similar and compared nausea, gastrointestinal diarrhea, tolerability vomiting this among Rates of VK-XXXX treated As in were prior studies, VK-XXXX patients demonstrated excellent placebo. in to

hypercholesterolemia consistent and in fatty findings Phase fat Xa XX-week are and a liver patients significant also in endpoints, liver plasma These with study VK-XXXX demonstrating The successfully evaluating Phase secondary both lipids. reductions trial non-alcoholic prior achieved its and Xa disease. primary with

durable, completion events Importantly, of of the The in fat tolerability liver patients dosing. promising majority the reported. also reductions safety four no XX-week with and demonstrated weeks were the study of after serious adverse with remaining responders VK-XXXX

secondary significant the VOYAGE of reduction, treatment properties, eight data after from half combined of route treatment therapeutic We fat best-in-class In by of of of the assessed VKXXXX's exploratory the hepatic to weeks of biopsy VOYAGE histologic including look study, and reporting NASH. XX the forward first the from a as objectives the changes evaluation in lipid XXXX. for belief tolerability, along that lowering the previously with trial support and excellent the our studies administration, our oral of liver the safety, results compound, view, establish completed broad top-line this with it

dual a Transitioning agonist in at this glucose to evaluated polypeptide, or data same the dose our the recent GLP-X or obese insulin treatment, treatment in newest weight with candidate program, as program GLP-X the I'll is period of following of peptide-X, time. is glucagon-like sensitivity, for [indiscernible] a vivo compared GIP among that the receptor, insulinotropic Initial and from VKXXXX now monolagonist when administered highlight a obesity. of receptor for improvements mice glucose-dependent progress control VKXXXX. being polypeptide the same and diet-induced demonstrated loss, to

compounds, animals treated to animals observed with liver the our generally the addition, fat were content observed treated reductions those larger, monolagonist. In in relative GLP-X among with among

findings, study on dose pharmacokinetic a and and safety, its as evaluate multiple impact on preliminary its as and these tolerability single dose profile, preclinical ascending well to Viking other VKXXXX potential ascending conducted exploratory X of Based Phase measures.

this Earlier demonstrated of benefit. of clinical safety safe profile compounds were VKXXXX humans. and escalating from VKXXXX that this tolerability, with doses predictable demonstrated a results study evaluated well enrolled doses promising single men and this of VKXXXX. portion The TK profile portion VK of announced healthy in trial results the that demonstrated tolerated, of women the characteristics and favorable of and year, ascending we positive and this study dose encouraging signs The and single

approximately Following square. TMAX These a multiple XX from this XXX with healthy portion single body hours, men to ascending XXX subcutaneous study The for doses, of VKXXXX of exposures. XX hours kilograms received per XX approximately half-life women once of and meter minimum mass index enrolled weekly hours, demonstrated a subjects dose to XX hours the VKXXXX and excellent therapeutic ranging days.

day reductions were All differences in or time portion and follow-up receiving XX VKXXXX demonstrated also up Statistically point, In of to demonstrated the in encouraging to study, days weight the placebo, mean weight the of significant X.X%. of to ranging receiving body compared up mean after ranging in tolerability relative clinical VKXXXX Cohorts signs last body to administered. at also baseline, was X%. this cohorts placebo VKXXXX weight dose maintained XX from reductions positive activity. improved VKXXXX demonstrated and body safety

improvements addition, levels relative cohorts glucose statistical demonstrated to cohorts VKXXXX achieved though created all In significance. in placebo, all plasma with not

repeat mild majority, and moderate. tolerability encouraging adverse were moderate, VKXXXX following gastrointestinal adverse reported and vast also mild safety or XX% related reported of events dosing. as The were of events also as observed and XX% single or demonstrated

these X further in a promising escalation titration doses quarter. believe be initiate we studies. future company on VKXXXX's to trial may VKXXXX this the in results, with of achieved we and with patients plan plans higher evaluate windows, that Phase Given X Phase obesity to Based dose tolerability, longer later

we formulation is formulation subcutaneously, administered In an this of of addition to the pursuing compound. that oral also are VKXXXX

Earlier ascending the concluded initiation ascending double-blind, randomized, the study Phase clinical placebo-controlled of VKXXXX. Phase of study X in of multiple year. is X extension single year, in a formulation portion this oral of earlier study announced an is the This minimum study and dosing. daily we of body days. a Exploratory weight the study dose healthy index The following dose evaluate per novel tablet receive pharmacokinetics endpoints study and days of XX who is evaluate safety, XX objective of mass meter the to square. the Subjects body VKXXXX plasma XX volunteers in kilograms oral of glucose. changes will oral for primary doses have a include tolerability and to The

and oral provide patients the of and subcutaneous compound's both We expand of the formulations phase market believe dosing options potential opportunity. availability potential with flexible could

We the expect to year. report the in initial fourth quarter results study this this from of

X-ALD. and with an candidate, is with is update available on that beta X-ALD thyroid disabled a function in acids. orally clinical genetic Xb VKXXXX I'll or agonist. VKXXXX, of have evaluated being an in long now trial Like Adrenoleukodystrophy VKXXXX. is hormone a rare third provide clinical mutations Phase transport VKXXXX disorder. small X-ALD peroxisomal a metabolic receptor fatty our molecule Patients of patients debilitating very chain the currently

are the to to X-ALD. and these onset accumulation As is long And very the unable patients of fatty efficiently believed to compounds a result, metabolize acids. progression chain contribute of

based X-ALD. adrenomyeloneuropathy of Phase or decision this study in currently form of prior dose-dependent X healthy the patients. is with advance is once the on The XXX exposures, demonstrated affecting AMN than more Xb consistent most In was approximately X-ALD daily enrolling Phase Viking of XX% study evidence doses. with evaluating a a AMN accumulation, from common to form program volunteers. VKXXXX of positive that patients and half-life results a study, no VKXXXX in anticipated

ongoing experienced receive safety in is study treatment with vital and multi-center for side Phase A. adult triglycerides, in also observed or no reported, measures. B no with dose-related trial cardiovascular effects, demonstrated apolipoprotein reductions cholesterol, or tolerability VKXXXX patients placebo-controlled, Subject and X encouraging serious and AMN. LDL VKXXXX events signs, double-blind, The GI randomized, signals profile and to male lipoprotein adverse

later once at objectives The XX the This of long to and expect exploratory changes to an the study study The enrollment in acids. and of study plasma primary administered safety, are enrol evaluate for levels VKXXXX assessment we year. also of very chain to tolerability days. daily fatty continues pharmacokinetics complete includes this

to position invest clinical half achievements of us in of as public continue well the the of and pipeline. funds announced common raising advancement of approximately $XXX in we also year, gross Viking Beyond a the offering These stock, expansion completed proceeds first both million. successful the our

Viking. with lead VK-XXXX In safe has With largest reductions program reductions development. while fat, conclusion, period agent cardioprotective therapeutic for top-line respect an significant demonstrating from study the our Xb data robust stage affirmed to exciting for effective best-in-class Phase fat the VKXXXX, oral is liver lipid providing VOYAGE deliver at reported this in of our VKXXXX to our a that any been Today, XXXX first belief half reductions. and benefits in features, through of continues liver

VKXXXX, our in to receptor company's Phase and body XX dosing. respect days X completed reductions With and demonstrated tolerability following promising agonist, weight recently GLP-X study of GIP the and safety significant

of obesity Phase Given these a positive this VKXXXX initiate plan X study to results, quarter. we in later

potential options important tablet opportunity. of compound's significantly a pursuing In that addition, the we dosing formulation patients believe molecule this market expand novel we offer will and are

patients the completing this Finally, enrolment to and we apathy or adrenal continues evaluates with in year. XB later mild VKXXXX anticipate Phase enrol, study

As we $XXX of in our milestones, of positioned are currently look cash well to aggressive our with million the sheet as to as well future, pipeline. support balance the ahead each we clinical with a approximately development anticipated strong others

concludes for open now Thanks today. we'll our joining and This the questions. Operator? call us, comments for for again prepared

answer We Please Raymond will question session. from come instructions] James. now go here and begin will ahead. our Seedhouse Steve And first with question the [Operator

underway for afternoon. later oral to first becomes third curious, a are the of clear, oral Good Phase to for data obesity with much next tablet add any going get year. a parallel can steps that about this then so there you're thanks? Wanted and if the Thanks formulation the quarter, so to formulation, Phase just necessary I you'll ask need strategically you sort instance, X for for you'd am specifically, preclinical data Phase for GLP-GIP IND study have like the taking tablet the that and to molecule, what question. X FDA it also X separate that in

Hey Steve, thanks for the questions.

would path formulation. the forward the So the SubQ for plan parallel

IND, So if information under I moving separate and think study a respect the it to Phase design seek we CMC-related FDA likely the will we that would in study. have be it, SubQ Phase in that will the requirements, think, be, don't anything similar X then into oral formulation be a forward. probably included promising, some looks but move to to would more likely gaining to With X

ADA also, a or and comparing easy the data of you have Okay, semi-glutite of tablet animal your of emerging tirzepatide oral Do thanks, pre-clinically through sort lot control comparisons molecules the and well. possible some sense against out as to Brian, Phase what's or at now version formulations guys for data to the X have there and pre-clinically. of a course you of and stacks was this with those Is pre-clinically how of formulation of presented subcutaneous GLP-X monoagonist do there up it now? oral

Yeah, it's good question. a

the that be on will it, efficacy the exposure for oral the not just but same it expect that's terrific doesn't know the achieve SubQ mean there's able to just a same -- And the we of to as I level don't SubQ, don't doubt we efficacy. that So opportunity it. be level as

but didn't, remembering models, XX% it in we -- at animal weight percentage they looked SubQ. the dose probably I I'm it was don't XX-day as very effective, of the and know, oral pursue that When the about any XX%. probably in XX%, it efficacy ranging as were XX-day the formulation at We the specific but perfectly. comparisons, models, and show, probably not was some effective does loss earlier good

SubQ. that, probably as so but effective on me or the XX% it as call don't is So

up to GLP-X a for of hands able to And control your of opposed of formulation, own some emerging stage molecules other on course. subcutaneous synthesize do have you the or your stacks these are versus as how clinical sense get oral candidate, you laterally just pre-clinically, it

lot get I that, seen, against, a want have little animal and models animals loss large bit into thus far encouraging, we and from don't we've a done of We've looks these weight with far. a Oh! little what have pretty, are that, we've to of compounds we comfortable as think bit I but the it seen but what think air done exposures of pretty bars, very tested with we're I but, as

for lot the a question. Thanks taking Okay.

question come next ahead. from will Please Our with go Jay Olson Oppenheimer.

Oh, hey, congrats thanks on taking all for the progress the and questions.

kind and be the you should XXXX year, looking about of talk this data what oral just you For data for expected to how plan disclose that? we later can

Jay. Sorry. Thanks, clinical pre-clinically? data the Did or say you

Clinical.

similar announced SubQ. be Oh, the roughly clinical. probably It to what would with we

and PK at changes. and weight and look tolerability we'd effects body safety preliminary So on

We MRI is everything PDFF else to parallel aren't the oral, but I with very SubQ. doing the think the

a that restrictions and Okay. is be dietary any there to QD dosing? And going around dosing are

dosing. QD is It

not anything disclosed problematic. on dosing but We we would are haven't whether particularly restrictions, there details think or don't be

some And about then shortage your talk enrolment for the great. can Okay, XXXX the supply of given of studies? ongoing cadence competing compounds, just weight you loss the for

Yeah, it's dry of and and a by is XXXX. a then spell enrolment. study bursts the little the from fits we think the a it a of enrolment you This and little but lumpy in in than burst but we have can with end little site have year, Australia, comes starts, single of data

similar So SubQ to it's the pattern. enrolment

question. last Okay, great and may be one

Beyond there in? that GIP, mechanisms GLP-X and other are for any interested obesity you're

metabolic have and a in particular. fairly obesity we robust Yeah, in effort disorders

coming in think more right some those I is talk now, projects about in got everything think prime we exciting not but the here. I quarters, hope house we've ready time to for but

you, Appreciate questions. the taking you Thank all Brian. Great.

next Please come with Lee will question ahead. Our from Truist. go Joon

our taking for questions. thanks and progress the all on congrats Okay,

formulation, and other weight words, of from peak that you and other have effect is weight the around versus question, bar oral Just formulation, different the of saw you so I there in for a loss to a regimen or XX% XX% makes to the that think extrapolation that follow prior considerations the study, up do in Phase X% your loss Steve's difficult are like X on placebo-adjusted dosing follow-up?

the difficult I relevant whether Joon. to dosing sledgehammer effect thanks, extrapolation very Yeah, really exists. an understand you're because animal levels people, Yeah, not just to aren't at is sort think that that of or are studies studies

benchmark know people So, I a just expectations as in that would use We don't in the people. be. wouldn't yet what for effect

testing remind that you're we it. in oral can Got formulation? how many arms And the

Yeah, then arms. We placebo, arms. that It flexibility the in in have at dose do be add we'd and four five the if oral will study just SubQ escalating study would be like formulation to arms like, cohort

Looking forward in results partner to year, you how think quickly you and And do for NASH, find data next potential good the VKXXXX for in first can assuming it partner? it terms a take half in -- are what a you such forward? of of looking could who

Yeah, think great well, its I question.

hope what data out. We're on which turn the depends like. we would look interest think to think the And that move as would I and see program. we to in Phase speed it the how study, of as biopsies soon I X the schedule drive excited will X and design outline meeting the FDA and discuss with a of the the upon forward, Phase in the completion possible to

go from Stifel. ahead Annabel next our Samimy will your question Please with question. And come with

the thinking for emerging? might patients? the end. How is have of Stacy start our And how agonist ADA you and those feel your following I single in This some Do on you to you and dual do Annabel. or that quarter landscape calling two the the triple. find new identifying populations than and more thanks for might about clinical Congrats guess suited taking our trials are orals you be that on the programs of question. Hi. strengths

least on been or potential tirzepatide encroachment triple from And it's NASH from for might the I opportunity? how seeing you're side Can about affect G interpreted. that's guess how feedback you talk at your your

have now. the and lot reminder, of is of an I of just, projected obesity the right drug. exciting. we drugs obesity new some data Stacy. very It obesity from thanks, And A uptake it uptake, Yeah, as talk a about how and looks looks how ADA

widely, got molecule a the the phenomenal great, that's VKXXXX. to extent think we've we are So because those used drugs in

point, we compelling drugs this obesity seen really At from signal. haven't the anti-fibrotic

So and of the I sense, may targeting agents drug. edge obesity mechanisms an think different in have type on an liver just some that

serve suggestion at to ADA really look conference for a so pure more setting to that's GI the favorable I to Nash, guidelines they're agent agent think when the and a conference, an we earlier at and think announced funnel where we versus Nash screen awareness of patients think, think awareness you update to more think great probably that obesity into is, that'll receive in NAFLD updated think that were more just the and the drugs. increase the raise ADA guidance. the specialist likely We targeted I to the I

of for large large period to end the like be and NASH, has of retatrutide someone necessarily are pre-substantial aren't there a very room don't day, There maybe and suitable they is who at If description market. fit coexist. will modalities but these NASH that the time, for have and people markets. But, something obese NASH. of multiple are obesity that would some populations be people plenty morbid

get If typically a at you Asians, look skinny NASH. they

world. So, over NASH obesity just we don't see taking drugs necessarily the

statement. I an think that's over

helpful. guys. you, really Thank That's

from Hsieh go Andy ahead. question, Please And our come with Blair. William will next

for Thanks taking my Great. question.

So, I have one for XXXX.

in to you short-time considerations be a Instead, about of that is intervals, in, especially really put about the such loss mentioned context in magnitude arm. determination, flexibility plateau. just sometimes in dose difference another add You they curious escalate, that what I'm don't especially of really the you'll making the when weight where some separate.

adding So, thinking about the into I'm that's that original curious arm.

and, then, it'll of normalize understanding versus versus curious you have helpful the you. of weekly Thank ratio get of in the And to dosing? be dosing kind of between that an dosing terms SubQ kind oral SubQ, to just if oral disclosed

Andy. thanks, Yeah,

and the not. just the flexibility the with we So, have dosing, protocol just to oral cohort add

or would understanding data. drivers be we be the exposure cohort. primary want decision the that and the make tolerability on We not Those add kind whether another data to have PK, would based to to of data

doses to some per we planned respect day, milligrams With the we're per day, milligrams then flexibility would and planned, doses, X milligrams have be per and X.X there at in then per said any the looking day I protocol. changes, so, are think day, those that and XX we make the previously XX if milligrams we

that's very it, helpful. Got

And our with question Yale go next ahead. will from & come Laidlaw Jen Co. Please

the and thanks taking I've two afternoon, Good here. got for questions.

first I the best you to that at The one adding necessarily the GGG forward from the SPC it that on follow-up. feel be meeting, and was is something the meeting least recent consider, for seems glucagon probably is to side the product, agonist, or question very was guys promising. you this strategy have My not to another it is you

thanks, Yale. Yeah,

the We have get our dual at What the the we agonist the hands, outperform given do target, it's benefit them of the loss profile. we relatively event triple think, GLPX I weight compounds to is and the here there, from change triple and incremental modest couldn't GIP. in some looked data is agonist, it's that in on the agonist on the, adverse significant see the

may hypersensitivity on challenges see be that out in those cardiac we'll would elevated those safety, So concerns not patient. every may it term, long be potentially potential with pan worth but and how or

of the signal. outside the be be two now, those of we're dual nice There enhancement right So other may agonist. to layered glucagon GLPX on could mechanisms looking and that provide a at GIP very

is And terms aspects going X your thanks. here, you're reveal color the sounds that's the to one maybe very and longer of level and study Sub-Q helpful which more Phase great. or trial in design for question what start. Okay, can in you of other duration just Any

thanks, Yeah, Yale.

in to dose a XX study up tie this up trade We to up to So to go plan we XX week we're milligrams. XX and It's levels. would going move the blocks XX to plan week study. three milligrams milligrams to in

at XX of you arm end weeks. on milligram the if you for four study, to are believe arm, I So that the the would about be randomized

data look later to helpful That's Okay, year. great. forward very this and

come Partners. from question next with Leerink Thomas will ahead. go our And Smith Please

Good Thanks guys. Hey, taking the questions. afternoon. for

X on think obesity should that's the Just forward comment week. additional what directly Phase venue a detailed detailed beyond datasets to whether just obesity you've I couple the reasonable line? And on a I program, we is presentation This Can you expectation. for looking to the guess presenting be your still alluded the top with data.

abstract and I thanks, sent late We Yeah, did breaker out. submit will when don't notifications those be Tom. an know a as

yet. would hope have We I'm sorry, different did looked also plasma to lipids collect lot lipids. plasma haven't to at fat. -- notified I looked say. And at is we and meant a liver we and we And of what we glucose plasma

color more well the those some maybe So of side. on around little bit PK some more things as as a

data. talked haven't expect a little We PK more lot have probably but a about PK, to bit

great. Okay,

comment on you IND And and regulatory so if little could just what US whether you the in the I wondering filed the you be? the gating IND I guess factors specifically, if could a elaborate you would have, and filing bit guess, on the if progress with to XXXX

Tom. thanks, Yeah,

the And that to window third still we filed hope now. be We start IND. recently have in -- quarter, we but study have the in to we're the not right able

factors any yet. that back So aren't aware that preclude today would we haven't of there we're heard gating but that,

it. Got

guess methodology you on are comment could consensus a you additional review. great. on referred just biopsy. pathologist, last equal get question histology or they're one you're how Okay, if the us efficacy review pathology trial latest or And the to or XX-week I FX if I FX, thoughts previously border one using the And your about on the latest entry. patients to adding pathologists considering they Maybe NASH commented on your on thinking or if a could the four, the second about have thoughts a maybe of to give for screen I voyage for just Are evaluation? know biopsy they just and changing what you've evaluation

secondary the Yeah, the of a any and initiated Tom. sends obviously must go FX you four when they consensus. cusp reader evolved of FX the I'm aware second would of keep two to still -- where reader a consensus now primary an have gradations, with things thus versus we not reader reach It's think of NAS anybody read a pathologists approach much to two since that and time thanks, We lot or reached to are on haven't the study. different they best that those sort far they served we're

that Phase currently I approach, us working maybe for we what's it's right a trial, now probably in to going move a So, In think stick the but would we're three with to now. reader protocol. X

guys. for it. question taking Got Great. the it. That's Appreciate Thanks helpful.

[Operator instructions] come next go with Our Please Justin will from Zelin question here BTIG. ahead.

for on taking progress question here. and the congrats the Thanks

an Brian, acquisition things So the space. out? Viking, saw the company recently the obesity BD us in into at latest bringing you either the thinking or give likewise on strategy Could we

yeah, Justin. thanks, Oh,

we today possible full. develop obesity company as launching new minded our or really as probably make plan our of a things is that's what we the company will Our say, a programs. to folks internal aggressively own the into things Right is I'd programs open ourselves see product, with an can. we but We far don't as to development be and as for either hands continue the as sense NASH our and things opportunities but priority that they given that bringing have shareholders, our arise lower on now, clinical

Great. so That makes question. me. Thanks to for the taking sense much

go Roth next MKM. our from ahead. Please will question, Dylan Dupuis come And with

question. Hi, my thank for taking you

that X the start. you Just are guys one Phase planning study quick obesity question to on

dosing implementing Just think you'll you point around to Thank and dose? need you. what the start at cohorts

doses three to fixed Yeah, doses lowest week the into titrate titrate and thanks, would subsequent would Phase higher Dylan. we dose, will those X.X study plan be mg the a X blocks. dose in but be Yeah, do in

So, to the then three and milligrams dose. a cohort milligrams for at at do of weeks second cohort trial mgs five X.X we example, is plan the remainder the X

So that's the how working. we scheme anticipate titration

Thanks, Dylan.

concludes our the back closing Stephanie this conference And session. remarks. for I'd turn to over like question-and-answer to any Diaz

participation updating coming look to your Viking for you all again and supportive you Therapeutics. continued Thank the Thank months. forward We in of you.

conference presentation. concluded. today's Thank now much attending you very for The has

lines. your disconnect now may You